Galmed Pharmaceuticals Ltd. (GLMD) Ownership
GLMD ownership summary
as of October 2, 2026- Institutions
- 1.9% of shares outstanding
- Insiders
- 3.04% of shares outstanding
- Shares outstanding
- 1.1M
- Float
- 976K shares available to trade
- Short interest
- 0.46% 37K shares short
- Days to cover
- 0.05 short interest down 74.7% vs prior month
- Institutions 1.89%
- Insiders 3.04%
- Other investors 95.07%
GLMD top institutional holders
16 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 1.04% | 87K | $314,401 | +75,469 (+663.1%) | June 30, 2026 |
| 2 | XTX Topco Ltd | 0.27% | 22K | $81,074 | +11,348 (+102.7%) | March 31, 2026 |
| 3 | Jane Street Group LLC | 0.20% | 16K | $59,531 | +4,310 (+35.5%) | March 31, 2026 |
| 4 | TWO SIGMA SECURITIES, LLC | 0.14% | 12K | $43,335 | −1,631 (−12.0%) | March 31, 2026 |
| 5 | UBS Group AG | 0.03% | 2,546 | $9,217 | +732 (+40.4%) | March 31, 2026 |
| 6 | BNP Paribas Arbitrage, SA | 0.01% | 600 | $2,172 | −300 (−33.3%) | March 31, 2026 |
| 7 | Morgan Stanley - Brokerage Accounts | <0.01% | 157 | $568 | −141 (−47.3%) | March 31, 2026 |
| 8 | Wells Fargo & Co | <0.01% | 43 | $156 | +34 (+377.8%) | March 31, 2026 |
| 9 | TSFG, LLC | <0.01% | 17 | $62 | — | June 30, 2026 |
| 10 | SBI Securities Co Ltd | <0.01% | 16 | $58 | — | March 31, 2026 |
| 11 | Federation des caisses Desjardins du Quebec | <0.01% | 14 | $51 | — | March 31, 2026 |
| 12 | Advisor Group Holdings, Inc. | <0.01% | 5 | $18 | — | March 31, 2026 |
| 13 | Hanson Mcclain Inc | 0.00% | 2 | $7 | — | March 31, 2026 |
| 14 | ZRC WEALTH MANAGEMENT, LLC | 0.00% | 2 | $7 | — | June 30, 2026 |
| 15 | Two Sigma Investments LLC | 0.00% | — | — | −80,177 (−100.0%) | June 30, 2026 |
| 16 | Dogwood Wealth Management LLC | 0.00% | — | — | −1 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 16, 5 holders added 92K shares and 5 cut 82K.
GLMD top mutual fund and ETF holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Nomura Healthcare Fund Class I | 0.02% | 1,701 | $6,158 | — | July 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
GLMD shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns GLMD
Institutional investors own 1.9% of Galmed Pharmaceuticals's shares and insiders 3.04%. The largest holder is Citadel Advisors Llc with 1.04% of the shares (87K), as of June 30, 2026. Among the top 16 institutions, 5 added shares and 5 reduced their stake in the latest filings. Short interest is 0.46% of the float, or 0.05 days of average trading volume. The share count rose 7,038.2% since 2014.
Related: GLMD analyst forecast, GLMD key metrics. See the GLMD stock overview for the latest quote and news.
GLMD ownership FAQ
Who owns the most Galmed Pharmaceuticals stock?
The largest shareholders of Galmed Pharmaceuticals are Citadel Advisors Llc (1.04%), XTX Topco Ltd (0.27%), Jane Street Group LLC (0.20%), TWO SIGMA SECURITIES, LLC (0.14%), UBS Group AG (0.03%).
What percentage of Galmed Pharmaceuticals is owned by institutions?
Institutions hold 1.9% of Galmed Pharmaceuticals's shares outstanding; insiders hold 3.04%.
Which funds own Galmed Pharmaceuticals?
The largest fund holders of Galmed Pharmaceuticals are Nomura Healthcare Fund Class I (0.02%).
What is Galmed Pharmaceuticals's short interest?
37K shares of Galmed Pharmaceuticals were sold short, 0.46% of the float; at the average daily volume it would take 0.05 days to cover.
How many shares of Galmed Pharmaceuticals are outstanding?
Galmed Pharmaceuticals has 1.1M shares outstanding, of which 976K are in the public float.